Metabolic Syndrome: Pipeline Analysis
and U.S. Market Forecast thoroughly
evaluates marketed therapies and new drugs in development for
the four conditions
comprising Metabolic Syndrome-dyslipidemia, obesity, type 2 diabetes,
The eligible treatment population in the U.S. for these four conditions
is currently 40 million patients and will nearly double over the
next 15 years, bringing unprecedented social and economic impacts.
Specifically, this report:
- Reveals the latest findings about the interactions among widely prevalent lifestyle factors such as poor nutrition, being overweight, and sedentary lifestyle, and how they contribute to insulin resistance, dyslipidemia, and high blood pressure.
the strengths and weaknesses of 13 R&D pipelines
focused on metabolic syndrome, comparing products
and mechanisms in each disease category against
one another and against the gold standard.
- Presents 15-year forecasts of sales in the U.S. of marketed and investigative therapies for each of the four disorders, taking into account unmet medical need, changes in epidemiology, patent expirations, and competitive drug launches.
- Spotlights the most promising drugs and early-stage mechanisms of action and the likely timeframe for their launch.
Figure 4.3. SWOT Diagram for Lipid-Lowering Drugs
Source: Hermann A.M. Mucke, Ph. D.
Decision makers in early-stage development are waking up to the need for solid market intelligence about competitor projects and the commercial potential of products in development. Forecasts are taking a central role in the commercial assessment of early-stage drug therapies, where they can serve as the repository of a company’s latest thinking on both commercial and clinical questions. Through a reliable, early-stage forecast and an assessment of products in development, Metabolic Syndrome: Pipeline Analysis and U.S. Market Forecast provides R&D managers with the clinical data, the analytical tools, and the market intelligence they need to make informed decisions about individual projects and portfolios.
About the Author
Hermann A.M. Mucke, Ph.D. spent 17 years in academia and industry before he founded H.M. Pharma Consultancy (www.hmpharmacon.com) in 2000 to become an independent pharmaceutical consultant, analyst and science author. His last industry position was Vice President R&D in a European pharmceutical company which he helped to take public on the Frankfurt Stock Exchange in 1999. Since then, Dr. Mucke, who holds a Ph.D. in biochemistry from the University of Vienna (Austria) became a consultant and advisory board member for several European and U.S. pharmaceutical companies, and a regular reviewer of drugs and patents for Thomson Current Drugs and Ashley Publications. He has served as an outside expert author for CHI since 2004. Dr. Mucke is based in Vienna and can be reached at email@example.com , or by fax at +43 1 494 9989.
Market forecasts for the component diseases of metabolic syndrome provided by Equinox Group, a leader in pharmaceutical new product forecasting. For more information, please visit http://www.equinox-group.com.